This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 3 of 577

Update: New Patient Receiving BlueBird Gene Therapy Responding More Slowly

By Adam Feuerstein

The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.

11:31AM 11/06/14

Epizyme Shares Weak on Disappointing Leukemia Drug Study Results

By Adam Feuerstein

New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.

11:12AM 11/06/14

After A Long Year, an Update on Geron's Myelofibrosis Drug Is Disclosed

By Adam Feuerstein

The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.

09:57AM 11/06/14

Aegerion Buys Rare Disease Therapy, Seeking Path Out of Current Troubles

By Adam Feuerstein

Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.

07:55AM 11/06/14

Celldex Therapeutics Shares Fall on Breast Cancer Study Changes

By Adam Feuerstein

Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more risk

04:26PM 11/05/14

Diabetes Analyst: Sanofi CEO's Firing May Spell Trouble for MannKind Afrezza Partnership

By Adam Feuerstein

Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.

01:40PM 11/04/14

FDA Review of Rockwell's Dialysis Therapy Raises Doubts About Need

By Adam Feuerstein

Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.

10:22AM 11/04/14

Super Important Biotech and Drug Stock Events for November

By Adam Feuerstein

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.

08:24AM 11/03/14

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:40AM 10/31/14

Aegerion Problems Mount With Poor Quarter and Reduced Guidance

By Adam Feuerstein

The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals, the company he runs as CEO, is falling apart.

05:07PM 10/30/14

Page 3 of 577

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs